Glancy Binkow & Goldberg LLP Announces Investigation of Inhibitex, Inc.

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims against the Board of Directors of Inhibitex, Inc. ( “Inhibitex” or the “Company”) (NASDAQ:INHX) related to the proposed acquisition of the Company by Bristol-Myers Squibb Co. The transaction is valued at approximately $2.5 billion or $26.00 per share.

The investigation concerns whether the Board of Directors of Inhibitex breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. The Company has seen substantial recent growth. Its share price has sky rocketed from $2.16 on March 2, 2011 to $15.51 on December 2, 2011.

If you are a shareholder of Inhibitex, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Louis Boyarsky, Esquire, Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067, by telephone at 310-201-9150 or Toll Free at 888-773-9224 or by email to shareholders@glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024